Cite

HARVARD Citation

    Hsu, C. et al. (n.d.). 2801 Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a hase 1b study. European journal of cancer. pp. S558-. [Online]. 
  
Back to record